Increased CD36 protein as a response to defective insulin signaling in macrophages.

Accelerated atherosclerosis is a major cause of morbidity and death in insulin-resistant states such as obesity and the metabolic syndrome, but the underlying mechanisms are poorly understood. We show that macrophages from obese (ob/ob) mice have increased binding and uptake of oxidized LDL, in part due to a post-transcriptional increase in CD36 protein. Macrophages from ob/ob mice are also insulin resistant, as shown by reduced expression and signaling of insulin receptors. Three lines of evidence indicate that the increase in CD36 is caused by defective insulin signaling: (a) Treatment of wild-type macrophages with LY294002, an inhibitor of insulin signaling via PI3K, results in an increase in CD36; (b) insulin receptor knockout macrophages show a post-transcriptional increase in CD36 protein; and (c) administration of thiazolidinediones to intact ob/ob mice and ob/ob, LDL receptor-deficient mice results in a reversal of macrophage insulin receptor defects and decreases CD36 protein. The last finding contrasts with the increase in CD36 that results from treatment of macrophages with these drugs ex vivo. The results suggest that defective macrophage insulin signaling predisposes to foam cell formation and atherosclerosis in insulin-resistant states and that this is reversed in vivo by treatment with PPAR-gamma activators.

[1]  R. Vigneri,et al.  Insulin receptor tyrosine kinase activity is reduced in monocytes from non-obese normoglycaemic insulin-resistant subjects , 1993, Diabetologia.

[2]  Jerrold M. Olefsky,et al.  Diabetes mellitus : a fundamental and clinical text , 2004 .

[3]  C. Glass,et al.  PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Kahn,et al.  The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. , 2003, The Journal of clinical investigation.

[5]  D. Mangelsdorf,et al.  Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Sampson,et al.  Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. , 2003, Atherosclerosis.

[7]  K. Moore,et al.  Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in Macrophages* , 2002, The Journal of Biological Chemistry.

[8]  S. Takasawa,et al.  Recent advances in the Okamoto model: the CD38-cyclic ADP-ribose signal system and the regenerating gene protein (Reg)-Reg receptor system in beta-cells. , 2002, Diabetes.

[9]  S. Haffner Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. , 2002, The American journal of cardiology.

[10]  S. Hazen,et al.  A Novel Family of Atherogenic Oxidized Phospholipids Promotes Macrophage Foam Cell Formation via the Scavenger Receptor CD36 and Is Enriched in Atherosclerotic Lesions* , 2002, Journal of Biological Chemistry.

[11]  R. Evans,et al.  Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis , 2002, Trends in Endocrinology & Metabolism.

[12]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[13]  A. Tall,et al.  Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. , 2002, Journal of lipid research.

[14]  C. Glass,et al.  Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux , 2002, Molecular and Cellular Biology.

[15]  A. Baron,et al.  Vascular function, insulin resistance and fatty acids , 2002, Diabetologia.

[16]  G. Reaven Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia , 2002, Diabetes, obesity & metabolism.

[17]  A. Tall,et al.  Transcriptional Profiling Reveals Global Defects in Energy Metabolism, Lipoprotein, and Bile Acid Synthesis and Transport with Reversal by Leptin Treatment in Ob/ob Mouse Liver* , 2001, The Journal of Biological Chemistry.

[18]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[19]  Carrie M. Welch,et al.  Preferential ATP-binding Cassette Transporter A1-mediated Cholesterol Efflux from Late Endosomes/Lysosomes* , 2001, The Journal of Biological Chemistry.

[20]  S. Perrey,et al.  Severe Hypercholesterolemia, Hypertriglyceridemia, and Atherosclerosis in Mice Lacking Both Leptin and the Low Density Lipoprotein Receptor* , 2001, The Journal of Biological Chemistry.

[21]  F. Maxfield,et al.  The Uptake and Degradation of Matrix-bound Lipoproteins by Macrophages Require an Intact Actin Cytoskeleton, Rho Family GTPases, and Myosin ATPase Activity* , 2001, The Journal of Biological Chemistry.

[22]  M. Linton,et al.  Class A scavenger receptors, macrophages, and atherosclerosis , 2001, Current opinion in lipidology.

[23]  R. Silverstein,et al.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. , 2001, The Journal of clinical investigation.

[24]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[25]  H. Koshiyama,et al.  Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  Timothy McCaffrey,et al.  A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation , 2001, Nature Medicine.

[27]  B. Egan,et al.  Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.

[28]  W. Hsueh,et al.  Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[29]  S. Perrey,et al.  Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[30]  J. Auwerx,et al.  Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Goldstein,et al.  Unsaturated Fatty Acids Down-regulate SREBP Isoforms 1a and 1c by Two Mechanisms in HEK-293 Cells* , 2001, The Journal of Biological Chemistry.

[33]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[34]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[35]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[36]  D. Altshuler,et al.  The role of PPAR-γ in macrophage differentiation and cholesterol uptake , 2001, Nature Medicine.

[37]  R. Silverstein,et al.  CD 36 : a class B scavenger receptor involved in angiogenesis , atherosclerosis , inflammation , and lipid metabolism , 2001 .

[38]  R. Evans,et al.  A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. , 2001, Molecular cell.

[39]  L. Chao,et al.  Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.

[40]  D. Matthews Diabetes Mellitus: A Fundamental and Clinical Text , 2000 .

[41]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[42]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[43]  T. Willson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. , 2000, The Journal of clinical investigation.

[44]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[45]  L. Limbird,et al.  Stimulation of Mitogen-activated Protein Kinase by G Protein-coupled α2-Adrenergic Receptors Does Not Require Agonist-elicited Endocytosis* , 1999, The Journal of Biological Chemistry.

[46]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[47]  D. Malide,et al.  Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation. , 1998, American journal of physiology. Endocrinology and metabolism.

[48]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[49]  P. Reaven,et al.  Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[50]  B. Spiegelman,et al.  Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. , 1997, The Journal of clinical investigation.

[51]  J. Graham,et al.  A quick, easy and inexpensive method for the isolation of human peripheral blood monocytes. , 1997, Journal of immunological methods.

[52]  M. Welham,et al.  Insulin Receptor Substrate-2 Is the Major 170-kDa Protein Phosphorylated on Tyrosine in Response to Cytokines in Murine Lymphohemopoietic Cells* , 1997, The Journal of Biological Chemistry.

[53]  Mark D. Johnson,et al.  Early neonatal death in mice homozygous for a null allele of the insulin receptor gene , 1996, Nature Genetics.

[54]  A. Skubitz,et al.  A Peptide Model of Basement Membrane Collagen α 1(IV) 531- 543 Binds the α3β1 Integrin (*) , 1995, The Journal of Biological Chemistry.

[55]  V. P. Knutson,et al.  Insulin Resistance Is Mediated by a Proteolytic Fragment of the Insulin Receptor (*) , 1995, The Journal of Biological Chemistry.

[56]  G. Zoppini,et al.  Phosphotyrosine protein profiles in monocytes after insulin and IGF‐1 stimulation , 1994, European journal of clinical investigation.

[57]  M. Krieger,et al.  Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). , 1994, Annual review of biochemistry.

[58]  R. Curi,et al.  Effects of insulin, glucocorticoids and thyroid hormones on the activities of key enzymes of glycolysis, glutaminolysis, the pentose-phosphate pathway and the Krebs cycle in rat macrophages. , 1992, The Journal of endocrinology.

[59]  M. Brown,et al.  Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. , 1983, Methods in enzymology.

[60]  C. Kahn,et al.  Insulin inhibition of antibody-dependent cytoxicity and insulin receptors in macrophages , 1977, Nature.

[61]  C. Kahn,et al.  Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting. , 1976, The Journal of clinical investigation.